The recommendation statements are as follows:
• Bone scan should not be employed in low risk prostate cancer patients
• Active surveillance is best available care for very low risk prostate cancer
• Active surveillance is preferred for low risk prostate cancer
- Clinicians may offer definitive treatment to select patients who may have high probability of progression
• While gland cryotherapy is not recommended as the side effects are considerable and no survival benefit has been demonstrated
• Focal therapy is not standard of care and comparative survival evidence is lacking
• Clinicians should recommend watchful waiting or observation (distinct from active surveillance) for men with a life expectancy less than 5 years.
• Among men with low risk prostate cancer, tissue-based biomarkers have not been shown to have a clear role in selection of candidates for active surveillance.
The full guidelines can be found at http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)
Presented By: Jeffrey Cadeddu, MD, University of Texas – Southwestern, Dallas, TX
Written By: Benjamin T. Ristau, MD, Fox Chase Cancer Center, Philadelphia, PA
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA